UnitedHealth Group Inc. (NYSE:UNH) has been given a $175.00 price target by investment analysts at Leerink Swann in a report issued on Wednesday. The brokerage currently has a a “buy” rating on the healthcare conglomerate’s stock. Leerink Swann’s target price would suggest a potential upside of 22.04% from the stock’s current price.
Other research analysts have also issued reports about the company. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $161.00 price target (up from $145.00) on shares of UnitedHealth Group in a research report on Friday, July 22nd. Vetr lowered UnitedHealth Group from a “buy” rating to a “hold” rating and set a $144.66 price target for the company. in a research report on Tuesday. Mizuho boosted their price target on UnitedHealth Group from $160.00 to $169.00 and gave the stock a “buy” rating in a research report on Wednesday. Citigroup Inc. boosted their price target on UnitedHealth Group from $148.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, July 20th. Finally, Barclays PLC boosted their price target on UnitedHealth Group from $151.00 to $164.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 20th. Two investment analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has assigned a strong buy rating to the company’s stock. UnitedHealth Group currently has an average rating of “Buy” and an average price target of $155.65.
UnitedHealth Group (NYSE:UNH) traded up 1.18% on Wednesday, reaching $145.08. The company’s stock had a trading volume of 4,197,054 shares. UnitedHealth Group has a 1-year low of $107.51 and a 1-year high of $146.36. The company has a market capitalization of $138.17 billion, a price-to-earnings ratio of 22.70 and a beta of 0.57. The firm’s 50 day moving average price is $137.12 and its 200-day moving average price is $136.75.
UnitedHealth Group (NYSE:UNH) last issued its earnings results on Tuesday, October 18th. The healthcare conglomerate reported $2.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.08 by $0.09. The business earned $46.30 billion during the quarter, compared to analyst estimates of $46.09 billion. UnitedHealth Group had a return on equity of 19.08% and a net margin of 3.51%. UnitedHealth Group’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.77 EPS. Equities analysts forecast that UnitedHealth Group will post $7.90 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 20th. Stockholders of record on Friday, September 9th were given a $0.625 dividend. The ex-dividend date of this dividend was Tuesday, September 6th. This represents a $2.50 dividend on an annualized basis and a dividend yield of 1.74%. UnitedHealth Group’s dividend payout ratio (DPR) is presently 39.12%.
In other news, Director Richard T. Burke sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $135.31, for a total value of $5,412,400.00. Following the completion of the sale, the director now directly owns 2,003,550 shares in the company, valued at $271,100,350.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.65% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of UNH. Omega Advisors Inc. bought a new stake in shares of UnitedHealth Group during the first quarter valued at about $64,386,000. Edgar Lomax Co. VA boosted its stake in shares of UnitedHealth Group by 0.7% in the first quarter. Edgar Lomax Co. VA now owns 503,143 shares of the healthcare conglomerate’s stock valued at $64,855,000 after buying an additional 3,438 shares during the last quarter. Gateway Investment Advisers LLC boosted its stake in shares of UnitedHealth Group by 8.8% in the second quarter. Gateway Investment Advisers LLC now owns 815,807 shares of the healthcare conglomerate’s stock valued at $115,192,000 after buying an additional 66,274 shares during the last quarter. Origin Asset Management LLP bought a new stake in shares of UnitedHealth Group during the first quarter valued at about $34,616,000. Finally, Panagora Asset Management Inc. boosted its stake in shares of UnitedHealth Group by 5.0% in the first quarter. Panagora Asset Management Inc. now owns 947,733 shares of the healthcare conglomerate’s stock valued at $122,163,000 after buying an additional 44,707 shares during the last quarter. Institutional investors own 85.80% of the company’s stock.
About UnitedHealth Group
UnitedHealth Group Incorporated is a diversified healthcare company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. The Company conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.